Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs KLA Corp. (KLAC) Price & Performance

Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs KLA Corp. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while KLA Corp. trades at $204.07 (market cap $251.82B). The key difference: KLA Corp. is far larger — about 5273.7× Cassava Sciences Inc's market cap, and KLA Corp. pays a 0.48% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAKLAC
Market Cap
$47.75M$251.82B
Sector
HealthTechnology
52-Week High
$4.64$301.71
52-Week Low
$0.87$84.39
Enterprise Value
-$34.93M$253.07B
Dividend Yield
0.48%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

KLA Corp.

KLA Corporation (KLAC) trades at $198.11, up 2.53% today, with a neutral technical signal despite bullish moving averages. The stock shows strong fundamentals, including a 35.57% net income margin and consistent earnings beats, with Q3 2026 EPS expected at $1.17. Recent corporate actions include a 1:10 stock split and a $2.30 dividend, while cash flow remains positive at $101.78M in 2025. Analyst sentiment is optimistic, with a $246.93 consensus price target implying significant upside.

The outlook for KLAC is positive, driven by AI-driven semiconductor demand and robust profitability, but risks include high valuation multiples and market volatility. Investment opportunities center on growth in advanced packaging, with Wall Street largely bullish; however, investors should monitor competitive pressures and economic cycles that could impact the chip equipment sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC